Home » FDA Approves Glaxo, XenoPort Drug Horizant For Shingles-Related Disease
FDA Approves Glaxo, XenoPort Drug Horizant For Shingles-Related Disease
The U.S. Food and Drug Administration has approved Horizant, a drug developed and marketed by GlaxoSmithKline and XenoPort for the management of postherpetic neuralgia, a nerve disease that sometimes follows shingles.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May